The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors

• Status: Completed
• Trial end date: 2011-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

This pilot study aims to address whether the prophylactic use of Cetrorelix Acetate after a long gonadotropin-releasing hormone (GnRH) agonist protocol post-hCG (human chorionic gonadotropin) administration can significantly reduce the incidence of OHSS in oocyte donors.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Virginia Center for Reproductive Medicine
• Treatments: Cetrorelix

Criteria

Inclusion Criteria:

• Prospective donors with BMIs between 19 and 28,

• Those with normal FSH levels and good antral follicle counts between 19-28 years of age, AND

• Donors would have passed all the required testing as mandated by VCRM and the FDA.

Exclusion Criteria:

• Oocyte donors exceeding a BMI of > 28,

• Those with any communicable diseases,

• Those with low antral follicle counts and small ovarian volumes,

• Those with elevated FSH levels,

• Those with positive sickle cell screen or cystic fibrosis screening,

• Smokers, OR

• Donors who are unable or unwilling to follow the research protocols.